EMA backs first low-carbon propellant for a licensed inhaler: what’s changing with Trixeo/Riltrava Aerosphere, and why it matters

The headline

On July 25, 2025, the European Medicines Agency (EMA) announced that it recommended a change in the propellant for two pressurised metered-dose inhalers (pMDIs) used in COPD—Trixeo Aerosphere and its duplicate product Riltrava Aerosphere. The current hydrofluorocarbon (HFC) propellant HFA-134a will be replaced with HFO-1234ze(E), a low-global-warming-potential (GWP) alternative. EMA highlights that this is the first reformulation of an inhaled medicine in the EU to adopt a more environmentally friendly propellant. European Medicines Agency (EMA)+2European Medicines Agency (EMA)+2

How big is the climate benefit? EMA and independent reporting describe a ~1000-fold / 99.9% reduction in GWP versus the current propellant, with similar physical properties that allow equivalent aerosol performance. European Medicines Agency (EMA)Reuters

This EU step follows the UK’s MHRA approval in May 2025 of the same switch for Trixeo—described as a “world first” low-carbon pMDI approval—after evidence showed the new propellant delivers the same dose and therapeutic effect as before. GOV.UK The Pharmaceutical Journal

What didn’t change

Active ingredients, dose, and dosing schedule remain the same. Patients continue using two inhalations twice daily. GOV.UK
Therapeutic intent and indications are unchanged (maintenance treatment in COPD). The change is only the gas that drives the spray. Medscape

What evidence did regulators consider?

Because the medicines themselves are unchanged, the key question for regulators was: does the new propellant deliver the same lung dose, performance and clinical effect? The assessments drew on:

In vitro and device-performance data
- Aerodynamic particle size distribution (APSD), emitted dose, spray pattern, leak, and valve performance under ICH conditions demonstrate functional equivalence with HFA-134a formulations. (Summarised by EMA/MHRA announcements.) European Medicines Agency (EMA)GOV.UK
Quality and stability packages
- Long-term and accelerated stability showed formulation and device integrity with HFO-1234ze(E). (Regulatory summaries reference quality/stability review.) GOV.UK
Therapeutic equivalence / clinical comparability
- The MHRA states the new propellant “delivers the same dose and therapeutic effect” as the original; EMA and trade coverage likewise report no change in safety/efficacy versus the legacy pMDI. While full trial dossiers aren’t public, AstraZeneca noted completion of a clinical programme supporting pMDI transitions to near-zero-GWP propellant. GOV.UK Reuters Medscape AstraZeneca

Takeaway: regulators accepted a totality-of-evidence approach (device/quality + therapeutic equivalence) rather than de-novo efficacy RCTs, because the actives and doses did not change—only the propellant did. European Medicines Agency (EMA)

Why HFO-1234ze(E)?

Near-zero GWP compared with HFA-134a, enabling ~99.9% lower climate impact per canister. Reuters Medscape
Compatible physicochemical profile for pMDIs, supporting comparable spray/particle characteristics after device optimization. ONdrugDelivery

AstraZeneca says the switch brings pMDI carbon footprints closer to dry-powder inhalers (DPIs)—without forcing patients who rely on pMDIs (e.g., due to inspiratory flow limitations) to change device type. Medscape

Practical implications for clinicians and patients

For prescribers & pharmacists

Expect updated packs of Trixeo/Riltrava with the new propellant as EU marketing authorisations are varied and supply transitions roll out. No dose changes or device-use retraining beyond standard inhaler counselling. European Medicines Agency (EMA)
Keep standard inhaler technique checks; suboptimal actuation-inhalation coordination still reduces efficacy, as with any pMDI.

For patients

Same medicine, same dose, same way to use it. If your inhaler looks/feels slightly different (spray plume sensation), that’s expected with a new propellant; it should not affect relief when used correctly. GOV.UK

Pharmacovigilance: what to watch post-switch

While no new safety signals are expected (actives unchanged), good vigilance focuses on device-mediated risks:

Dose delivery consistency & device function: monitor any spikes in reports of under-delivery, clogged nozzles, valve sticking, or dose-counter issues as markets transition. Report via EudraVigilance (EU) or Yellow Card (UK). European Medicines Agency (EMA)GOV.UK
Effectiveness in real use: track exacerbation rates, rescue medication use, and peak-flow trends to detect any unanticipated performance drift.
Patient experience: differences in plume feel/taste or throat sensation can affect adherence—capture patient-reported outcomes early.
Supply and substitution: ensure pharmacy systems flag the propellant-updated SKUs correctly to avoid confusion and maintain continuity of care.

Regulators and media note equivalent therapeutic effect, but real-world pharmacovigilance is essential during any large-scale device transition. GOV.UK Reuters

Public-health impact (real-world lens)

Climate wins without sacrificing care: pMDIs contribute materially to healthcare emissions because HFC propellants are potent greenhouse gases. Moving high-volume COPD/asthma pMDIs to HFO-1234ze(E) can cut inhaler-related emissions by ~85–99.9%, depending on baseline and portfolio mix—supporting EU and NHS net-zero strategies while preserving a familiar device option. Medscape Health Innovation East
Equity & adherence: many patients—older adults, those with low inspiratory flow, or coordination difficulties—need pMDIs. A lower-GWP pMDI avoids forcing a device switch that could harm adherence or outcomes. ONdrugDelivery
Industry signal: This is a market-shaping precedent. Competitors are racing to update pMDIs and meet Kigali/Montreal Protocol-aligned HFC phase-downs; broader adoption could meaningfully lower the respiratory sector’s carbon footprint. Financial Times

Bottom line

The EMA’s green light to reformulate Trixeo/Riltrava Aerosphere with HFO-1234ze(E) is a first-of-its-kind EU decision that keeps treatment the same for patients and clinicians, while dramatically reducing the inhaler’s climate impact. The clinical story is straightforward—same medicines, same dose, equivalent delivery—and the public-health upside is significant if the rest of the pMDI class follows suit. European Medicines Agency (EMA)GOV.UK Reuters

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.